Clinical Trial

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multicenter, single-arm, two-part study designed to evaluate the safety and efficacy of Lutetium \[177Lu\] Oxyoctreotide Injection in patients with inoperable, locally advanced or metastatic, progressive, advanced somatostatin receptor (SSTR) positive neuroendocrine neoplasms (NEN) other than grade G1/G2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and Neuroendocrine Carcinoma（NEC）.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-01; most recent amendment 2026-07-15.
Status change: Active, Not Recruiting → Recruiting 2026-07-15
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-08-28
Trial Details
NCT Number NCT06398444
Lead Sponsor Sinotau Pharmaceutical Group
Conditions Advanced Neuroendocrine Neoplasm
Enrollment 85 participants
Start Date 2024-06-11
Primary Completion 2027-06-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-17